C-Reactive Protein Inhibits Endothelium-Dependent NO-Mediated Dilation in Coronary Arterioles by Activating p38 Kinase and NAD(P)H Oxidase

Objective—Elevated levels of C-reactive protein (CRP), a proinflammatory marker, are associated with reduced systemic endothelium-dependent NO-mediated dilation in patients with coronary artery disease; however, the direct effect of CRP on coronary microvascular reactivity remains unknown. Herein, we examined whether CRP can modulate endothelium-dependent NO-mediated dilation of coronary arterioles and whether proinflammatory signaling pathways such as stress-activated protein kinases (p38 and c-Jun N-terminal kinase [JNK]) and oxidative stress are involved in the CRP-mediated effect. Methods and Results—Porcine coronary arterioles were isolated and pressurized without flow for in vitro study. Intraluminal treatment with a clinically relevant concentration of CRP (7 &mgr;g/mL; 1 hour) significantly attenuated the NO release and vasodilation to serotonin. Further incubation with the NO precursor l-arginine (3 mmol/L) partially restored serotonin-induced vasodilation. In the presence of superoxide scavenger 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), NAD(P)H oxidase inhibitor apocynin, or p38 kinase (an upstream activator of NAD(P)H oxidase) inhibitor SB203850, but not xanthine oxidase inhibitor allopurinol or JNK inhibitor SP600125, the detrimental effect of CRP on serotonin-induced dilation was prevented. Dihydroethidium staining showed that CRP produced SB203850- and TEMPOL-sensitive superoxide production in the arteriolar endothelium. CRP treatment of coronary arterioles significantly increased NAD(P)H oxidase activity. Conclusions—CRP inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by producing superoxide from NAD(P)H oxidase via p38 kinase activation. By impairing endothelium-dependent NO-mediated vasoreactivity, CRP could facilitate the initiation of numerous cardiovascular diseases.

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  S. Fichtlscherer,et al.  C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. , 2004, European heart journal.

[3]  K. Chayama,et al.  Relation between C reactive protein concentrations and coronary microvascular endothelial function , 2004, Heart.

[4]  S. Devaraj,et al.  C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.

[5]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[6]  R. Clempus,et al.  Vascular NAD(P)H oxidases: specific features, expression, and regulation. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[7]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[8]  S. Verma,et al.  C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.

[9]  Y. Hattori,et al.  Vascular smooth muscle cell activation by C-reactive protein. , 2003, Cardiovascular research.

[10]  Gabor Kaley,et al.  Increased Superoxide Production in Coronary Arteries in Hyperhomocysteinemia: Role of Tumor Necrosis Factor-&agr;, NAD(P)H Oxidase, and Inducible Nitric Oxide Synthase , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[11]  L. Kuo,et al.  Divergent Roles of Angiotensin II AT1 and AT2 Receptors in Modulating Coronary Microvascular Function , 2003, Circulation research.

[12]  S. Devaraj,et al.  C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.

[13]  Edward T H Yeh,et al.  Coming of age of C-reactive protein: using inflammation markers in cardiology. , 2003, Circulation.

[14]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[15]  K. Huber,et al.  High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. , 2002, American heart journal.

[16]  John Regan,et al.  The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. , 2002, Current topics in medicinal chemistry.

[17]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[18]  S. Verma,et al.  Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein , 2002, Circulation.

[19]  F. Faraci,et al.  Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. , 2002, American journal of physiology. Heart and circulatory physiology.

[20]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Dorrance,et al.  NADH/NADPH Oxidase and Enhanced Superoxide Production in the Mineralocorticoid Hypertensive Rat , 2001, Hypertension.

[22]  L. Kuo,et al.  Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide‐mediated vasodilatory function , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[24]  K. Channon,et al.  Enhanced Superoxide Production in Experimental Venous Bypass Graft Intimal Hyperplasia: Role of NAD(P)H Oxidase , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[25]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[26]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  L. Kuo,et al.  cAMP-independent dilation of coronary arterioles to adenosine : role of nitric oxide, G proteins, and K(ATP) channels. , 1999, Circulation research.

[28]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[29]  A. Shah,et al.  Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. , 1998, Cardiovascular research.

[30]  J. Zweier,et al.  Validation of Lucigenin (Bis-N-methylacridinium) as a Chemilumigenic Probe for Detecting Superoxide Anion Radical Production by Enzymatic and Cellular Systems* , 1998, The Journal of Biological Chemistry.

[31]  P. Gallop,et al.  An NADPH oxidase superoxide-generating system in the rabbit aorta. , 1995, The American journal of physiology.

[32]  J. Stolk,et al.  Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. , 1994, American journal of respiratory cell and molecular biology.

[33]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[34]  P. Kaminski,et al.  NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. , 1994, The American journal of physiology.

[35]  M. J. Davis,et al.  Endotoxin impairs flow-induced vasodilation of porcine coronary arterioles. , 1992, The American journal of physiology.

[36]  L. Kuo,et al.  Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. , 1991, The American journal of physiology.

[37]  M. Marcus,et al.  Microvascular distribution of coronary vascular resistance in beating left ventricle. , 1986, The American journal of physiology.

[38]  J. Zweier,et al.  Viswanathan Natarajan Cells Regulation by Map Kinases in Human Lung Endothelial Hyperoxia-induced Nad(p)h Oxidase Activation And , 2002 .

[39]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[40]  E. Fernandes,et al.  Progress towards the discovery of xanthine oxidase inhibitors. , 2002, Current medicinal chemistry.

[41]  J. Liao,et al.  oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles. , 2000, American journal of physiology. Heart and circulatory physiology.

[42]  C. Wilcox,et al.  Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. , 1999, Hypertension.

[43]  H. Ishizaka,et al.  Acidosis-induced coronary arteriolar dilation is mediated by ATP-sensitive potassium channels in vascular smooth muscle. , 1996, Circulation research.

[44]  P. D. Henry,et al.  Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. , 1987, The Journal of clinical investigation.